Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00037882 · ClinicalTrials.gov registry record · Phase 2

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Terminated
Registry status
Phase 2
Development phase
1
Enrollment target

NCT00037882: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT00037882 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00037882, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.

TERMINATED
Registry status
Phase 2
Development phase
1 participants
Enrollment target

Study Summary

The purpose of this study is to determine if PEG-Intron is better tolerated and more efficacious than standard interferons (Roferon, Intron) in patients with Philadelphia-positive Chronic Myelogenous Leukemia. These patients should have previously received standard interferon therapy and have been intolerant, resistant, or have relapsed disease.

Interventions

  • DRUG PEG-Intron

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2001-02
Est. Completion 2003-12-03
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

Why NCT00037882 stopped before completion

NCT00037882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which PEG-Intron is the first listed.

NCT00037882 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00037882 about?

NCT00037882 is a clinical study titled "PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron". The purpose of this study is to determine if PEG-Intron is better tolerated and more efficacious than standard interferons (Roferon, Intron) in patients with Philadelphia-positive Chronic Myelogenous Leukemia. These patients should have previously received standard interferon therapy and have been i...

What is the current status of trial NCT00037882?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2001-02. Estimated completion is 2003-12-03.

What interventions are being tested in trial NCT00037882?

The interventions under investigation include: PEG-Intron (DRUG).

Who is sponsoring clinical trial NCT00037882?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00037882's enrollment target sits among peer trials

1 2001st of 2000 the lowest of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00037882, the US trial registry maintained by the National Library of Medicine. NCT00037882 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.